Maxim raised the firm’s price target on Sensus Healthcare to $10 from $7 and keeps a Buy rating on the shares. The company’s Q1 results were significantly above estimates, with large customer driving its sales growth, the analyst tells investors in a research note. Sensus also had $14.7M in cash and no debt, and based on Maxim’s assumptions, the company may only need additional capital for acquisitions, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRTS:
- Sensus Healthcare Reports First Quarter 2024 Financial Results With Revenues up More than Three-fold
- Largest Veterinary Emergency Hospital in Tel Aviv Acquires Sensus Healthcare’s SRT-100™ to Provide Gentler Radiotherapy to Treat Tumors in Dogs and Cats
- Sensus Healthcare announces sale of first SRT-100 Vision System to Asia
- Sensus Healthcare to Host First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 9, 2024
- Navigating Uncertainty: How Global Crises Threaten Sensus Healthcare’s Growth and Operations